Evidence map›Paper›PMID 26160871›Full record

ArticleThe European respiratory journal2015

Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands.

Marie-Josée J Mangen, Mark H Rozenbaum, Susanne M Huijts, Cornelis H van Werkhoven, Douwe F Postma, Mark Atwood, Anna M M van Deursen, Arie van der Ende, Diederick E Grobbee, Elisabeth A M Sanders and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The European respiratory journal, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

66 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. The impact of 13-valent pneumococcal conjugate vaccination on virus-associated community-acquired pneumonia in elderly: Exploratory analysis of the CAPiTA trial.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2018
    Trial
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Pneumococcal vaccines in China.Human vaccines & immunotherapeutics · 2025
    Review
  20. Article

6 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Marie-Josée J MangenJulius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands These authors contributed equally m.j.j.mangen@umcutrecht.nl.
Mark H RozenbaumPfizer, Capelle a/d IJssel, The Netherlands Unit of Pharmacoepidemiology and PharmacoEconomics (PE2), Department of Pharmacy, University of Groningen, Groningen, The Netherlands These authors contributed equally.
Susanne M HuijtsJulius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands Department Respiratory Medicine, University Medical Center Utrecht, Utrecht, The Netherlands These authors contributed equally.
Cornelis H van WerkhovenJulius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands.
Douwe F PostmaJulius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands.
Mark AtwoodPolicy Analysis Inc., Brookline, MA, USA These authors are listed alphabetically.
Anna M M van DeursenJulius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands Spaarne Gasthuis Academie, Spaarne Gasthuis, Hoofddorp, The Netherlands Department of Pediatric Immunology and Infectious Diseases, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, The Netherlands These authors are listed alphabetically.
Arie van der EndeDepartment of Medical Microbiology, Netherlands Reference Laboratory for Bacterial Meningitis, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands These authors are listed alphabetically.
Diederick E GrobbeeJulius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands Julius Clinical, Academic Contract Research Organization, Zeist, The Netherlands These authors are listed alphabetically.
Elisabeth A M SandersDepartment of Pediatric Immunology and Infectious Diseases, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, The Netherlands These authors are listed alphabetically.
Reiko SatoPfizer Inc., Collegeville, PA, USA These authors are listed alphabetically.
Theo J M VerheijJulius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands These authors are listed alphabetically.
Conrad E VissinkJulius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands These authors are listed alphabetically.
Marc J M BontenJulius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, The Netherlands Joint senior authors.
G Ardine de WitJulius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands Joint senior authors.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA) demonstrated the efficacy of 13-valent pneumococcal conjugate vaccine (PCV13) in preventing vaccine-type community-acquired pneumonia and vaccine-type invasive pneumococcal disease in elderly subjects. We examined the cost-effectiveness of PCV13 vaccination in the Netherlands. Using a Markov-type model, incremental cost-effectiveness ratios (ICER) of PCV13 vaccination in different age- and risk-groups for pneumococcal disease were evaluated using a societal perspective. Estimates of quality-adjusted life-years (QALYs), costs, vaccine efficacy and epidemiological data were based on the CAPiTA study and other prospective studies. The base-case was PCV13 vaccination of adults aged 65-74 years compared to no vaccination, assuming no net indirect effects in base-case due to paediatric 10-valent pneumococcal conjugate vaccine use. Analyses for age- and risk-group specific vaccination strategies and for different levels of hypothetical herd effects from a paediatric PCV programme were also conducted. The ICER for base-case was €8650 per QALY (95% CI 5750-17,100). Vaccination of high-risk individuals aged 65-74 years was cost-saving and extension to medium-risk individuals aged 65-74 years yielded an ICER of €2900. Further extension to include medium- and high-risk individuals aged ≥18 years yielded an ICER of €3100.PCV13 vaccination is highly cost-effective in the Netherlands. The transferability of our results to other countries depends upon vaccination strategies already implemented in those countries.

Indexed as

AdolescentAdultAgedAged, 80 and overCost-Benefit AnalysisFemaleHumansMaleMarkov ChainsMiddle AgedNetherlandsPneumococcal InfectionsPneumococcal VaccinesProspective StudiesQuality-Adjusted Life YearsVaccination13-valent pneumococcal vaccinePneumococcal Vaccines

Identifiers

PMID26160871
PMCPMC4750466

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.